Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie til at undersøge sikkerheden, farmakokinetikken og den foreløbige effekt af IDE574-terapi hos voksne deltagere med fremskredne solide tumorer

2. november 2026 opdateret af: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

155

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Santa Monica, California, Forenede Stater, 90404-2095
        • Aktiv, ikke rekrutterende
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06510-3206
        • Rekruttering
        • Yale School of Medicine - Cedar Street
        • Ledende efterforsker:
          • Patricia LoRusso, MD
        • Kontakt:
    • Florida
      • Plantation, Florida, Forenede Stater, 33322
        • Rekruttering
        • Florida Clinical Trials Group
        • Ledende efterforsker:
          • Harshad Amin, MD
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322-1013
        • Rekruttering
        • Winship Cancer Institute, Emory University
        • Ledende efterforsker:
          • Shipra Gandhi, MD
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110-1010
        • Rekruttering
        • Washington University - Siteman Cancer Center
        • Ledende efterforsker:
          • Faisal Fa'ak, MD
        • Kontakt:
    • New Jersey
      • East Brunswick, New Jersey, Forenede Stater, 08816
        • Rekruttering
        • START Astera, LLC
        • Ledende efterforsker:
          • Bruno Fang, MD
        • Kontakt:
    • New York
      • Lake Success, New York, Forenede Stater, 11042
        • Rekruttering
        • START New York Long Island, LLC
        • Ledende efterforsker:
          • Geraldine O'Sullivan Coyne, MD
        • Kontakt:
      • New York, New York, Forenede Stater, 10032-3729
        • Aktiv, ikke rekrutterende
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI Oncology Partners - PPDS
        • Ledende efterforsker:
          • Sarah Premji, MD
        • Kontakt:
    • Texas
      • Austin, Texas, Forenede Stater, 78758
      • Dallas, Texas, Forenede Stater, 75039
      • Fort Worth, Texas, Forenede Stater, 76104
        • Rekruttering
        • START Dallas Fort Worth, LLC
        • Ledende efterforsker:
          • Henry Xiong, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030-4009
        • Rekruttering
        • MD Anderson Cancer Center
        • Ledende efterforsker:
          • Timothy Yap, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77054
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • NEXT Texas LLC - San Antonio
        • Ledende efterforsker:
          • David Sommerhalder, MD
        • Kontakt:
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • Start San Antonio, LLC
        • Ledende efterforsker:
          • Amita Patnaik, MD
        • Kontakt:
    • Utah
      • West Valley City, Utah, Forenede Stater, 84119
        • Rekruttering
        • START Mountain Region, LLC
        • Ledende efterforsker:
          • William McKean, MD
        • Kontakt:
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Georgien, 6000
        • Rekruttering
        • High Technology Hospital MedCenter Ltd
        • Ledende efterforsker:
          • Tamta Makharadze, MD
        • Kontakt:
      • Tbilisi, K'alak'i T'bilisi, Georgien, 114
        • Rekruttering
        • Pineo Medical Ecosystem
        • Kontakt:
        • Ledende efterforsker:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Georgien, 112
        • Aktiv, ikke rekrutterende
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Georgien, 144
        • Aktiv, ikke rekrutterende
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Georgien, 186
        • Aktiv, ikke rekrutterende
        • LLC Caucasus Medical Centre

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 99 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Eksperimentel: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Eksperimentel: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Eksperimentel: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Tidsramme: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Tidsramme: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Tidsramme: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Tidsramme: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Sekundære resultatmål

Resultatmål
Tidsramme
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Tidsramme: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Tidsramme: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Tidsramme: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Tidsramme: total study duration
total study duration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. marts 2026

Primær færdiggørelse (Anslået)

31. december 2029

Studieafslutning (Anslået)

31. januar 2030

Datoer for studieregistrering

Først indsendt

1. april 2026

Først indsendt, der opfyldte QC-kriterier

14. april 2026

Først opslået (Faktiske)

20. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • IDE574-001
  • 178299 (Anden identifikator: Regulatory Agency Identifier Number (s))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .